PCSK9 Inhibitors
Trials Results

Alirocumab - Bococizumab - Evolocumab

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

cardiovascular prevention

alirocumab
ODYSSEY Alternativealirocumabplacebo (on top statins)NegativeNCT01709513
ODYSSEY MONOalirocumabezetimibe aloneNegativeNCT01644474
ODYSSEY FH 1alirocumabplacebo (on top statins) - NCT01623115
ODYSSEY FH 2alirocumabplacebo (on top statins) - NCT01709500
ODYSSEY HIGH FH alirocumabplacebo (on top statins)NegativeNCT01617655
ODYSSEY OPTIONS Ialirocumabezetimibe (on top statin)Negative
ODYSSEY OPTIONS IIalirocumabezetimibe (on top statin)Negative
ODYSSEY COMBOalirocumabplacebo (on top statins)NegativeNCT01644175
ODYSSEY COMBO IIalirocumabplacebo (on top statins)NegativeNCT01644188
ODYSSEY Long-Term, 2015alirocumabplacebo (on top statins) Exploratory Suggesting NCT01507831
ODYSSEY OUTCOMES, 2018alirocumabplacebo (on top statins) Low risk of bias ConclusiveNCT01663402
CHOICE II ongoing alirocumab - NCT02023879
CHOICE I ongoing alirocumab - NCT01926782
NCT01288469 ongoing alirocumab - NCT01288469
bococizumab
SPIRE-1 ongoing bococizumabplacebo - NCT01975376
SPIRE-2 ongoing bococizumabplacebo - NCT01975389
SPIRE-SI ongoing bococizumabplacebo - NCT02135029
SPIRE-HR ongoing bococizumabplacebo - NCT01968954
SPIRE-LDL ongoing bococizumabplacebo - NCT01968967
SPIRE-FH ongoing bococizumabplacebo - NCT01968980
SPIRE-LL ongoing bococizumabplacebo - NCT02100514
evolocumab
MENDEl 2evolocumab - NCT01763827
LAPLACE-TIMI 57evolocumabplacebo (on top statins) - NCT01380730
RUTHERFORD-1evolocumabplacebo (on top statins)NegativeNCT01375751
GAUSS 2evolocumabezetimibe aloneNegative NCT01763905
Mendel 1, 2012evolocumab - NCT01375777
GAUSS 1, 2012evolocumabplaceboNegativeNCT01375764
DESCARTES, 2014evolocumabplacebo (on top statins)NegativeNCT01516879
YUKAWA-1, 2014evolocumab -
LAPLACE 2, 2014evolocumabplacebo (on top statins)NegativeNCT01763866
RUTHERFORD-2, 2015evolocumabplacebo (on top statins)NegativeNCT01763918
FOURIER, 2017evolocumabplacebo (on top statins) Low risk of bias ConclusiveNCT01764633



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons